|
|
|
| Efficacy of CD38 monoclonal antibody in the treatment of relapsed refractory multiple myeloma |
| ZHANG Dandan, WANG Hua* |
| The Second Clinical Medical College, Binzhou Medical University, Yantai 264003, Shandong, P. R. China |
|
|
|
|
Abstract The incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of treatment has improved outcomes in patients with multiple myeloma over the years, but MM is still incurable, and all patients will eventually relapse. CD38 monoclonal antibody has shown certain clinical efficacy in the treatment of relapsing refractory multiple myeloma. This article will review the mechanism of action of CD38 monoclonal antibody, and review the progress of two kinds of CD38 monoclonal antibodies, isatuximab and daratuumab, in the treatment of RRMM.
|
|
Received: 13 November 2020
|
|
|
|
|
|
[1] 况小红,童浩,代明辉,等.全球MM发病和死亡现状及其与人类发展指数的关系[J].现代肿瘤医学,2021,29(2):302-306.
[2] 鲍雪临,王华.泊沙康唑与急性髓系白血病的真菌预防[J].滨州医学院学报,2018,41(2):145-148.
[3] KUMAR S K, DIMOPOULOS M A, KASTRITIS E, et al. Natural history of relapsed myeloma,refractory to immunomodulatory drugs and proteasome inhibitors:a multicenter IMWG study[J].Leukemia,2017,31(11):2443-2448.
[4] FENG X, ZHANG L, ACHARYA C, et al. Targeting CD38 suppresses induction and function of t regulatory cells to mitigate immunosuppression in multiple myeloma[J].Clin Cancer Res,2017,23(15):4290-4300.
[5] VIOLA D, DONA A, CASERTA E, et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting[J].Leukemia,2021,35(1):189-200.
[6] MORENO L, PEREZ C, ZABALETA A, et al. The Mechanism of Action of the Anti-CD38 monoclonal antibody isatuximab in multiple myeloma[J]. Clin Cancer Res.,2019,25(10):3176-3187.
[7] LOKHORST H M, PLESNER T, LAUBACH J P, et al.Targeting CD38 with daratumumab monotherapy in multiple myeloma[J]. N Engl J Med,2015,373(13):1207-1219.
[8] LONIAL S,WEISS B M,USMANI S Z, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial[J].Lancet,2016,387(10027):1551-1560.
[9] USMANI S Z, NAHI H, PLESNER T, et al.Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials[J].Lancet Haematol,2020,7(6):e447-e455.
[10] CHARI A,LONIAL S,MARK T M, et al. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma[J].Cancer,2018,124(22):4342-4349.
[11] JULLIEN M,TRUDEL S,TESSOULIN B, et al. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study[J].Ann Hematol,2019,98(6):1435-1440.
[12] MATEOS M V, SONNEVELD P, HUNGRIA V, et al. Daratumumab,bortezomib,and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma:three-year follow-up of CASTOR[J].Clin Lymphoma Myeloma Leuk,2020,20(8):509-518.
[13] CHARI A,MARTINEZ-LOPEZ J,MATEOS M V, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma[J]. Blood,2019,134(5):421-431.
[14] DIMOPOULOS M,QUACH H,MATEOS M V, et al. Carfilzomib,dexamethasone,and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR):results from a randomised,multicentre,open-label,phase 3 study[J]. Lancet,2020,396(10245):186-197.
[15] PLESNER T,ARKENAU H T, GAY F, et al. Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503):final results of an open-label,phase 1/2 study[J].Br J Haematol,2019,186(3):e35-e39.
[16] JONATHAN L, KAUFMA N, SAAD Z,et al.Four-year follow-up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or refractory multiple myeloma (RRMM)[J].Blood,2019,134 (Supplement 1): 1866.
[17] CHARI A,SUVANNASANKHA A,FAY J W, et al.Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma[J].Blood,2017,130(8):974-981.
[18] SIEGEL D S,SCHILLER G J,SAMARAS C, et al. Pomalidomide, dexamethasone,and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment[J].Leukemia,2020,34(12):3286-3297.
[19] KAUFMAN J L,BAZ R C,HARRISON S J,et al.Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, bortezomib,in patients with relapsed/redractory multiple myeloma[J].Journal of Clinical Oncology,2020,38(15): 8511.
[20] MARTIN T,STRICKLAND S,GLENN M,et al.Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma[J].Blood Cancer J,2019,9(4):41.
[21] Turgut M, Moreau P, Dimopoulos M, et al. Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study - ScienceDirect[J]. Hematology, Transfusion and Cell Therapy, 2020, 42:51-52.
[22] MARTIN T,BAZ R,BENSON D M, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma[J].Blood,2017,129(25):3294-3303. |
|
|
|
